ZA200210312B - Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. - Google Patents
Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. Download PDFInfo
- Publication number
- ZA200210312B ZA200210312B ZA200210312A ZA200210312A ZA200210312B ZA 200210312 B ZA200210312 B ZA 200210312B ZA 200210312 A ZA200210312 A ZA 200210312A ZA 200210312 A ZA200210312 A ZA 200210312A ZA 200210312 B ZA200210312 B ZA 200210312B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- composition
- substance
- interferon
- alkyl
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title claims description 81
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 14
- 239000003001 serine protease inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 166
- 238000000034 method Methods 0.000 claims description 51
- 229940079322 interferon Drugs 0.000 claims description 44
- -1 enantiomers Chemical class 0.000 claims description 38
- 102000014150 Interferons Human genes 0.000 claims description 37
- 108010050904 Interferons Proteins 0.000 claims description 37
- 239000000651 prodrug Substances 0.000 claims description 32
- 229940002612 prodrug Drugs 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 108091005804 Peptidases Proteins 0.000 claims description 26
- 239000004365 Protease Substances 0.000 claims description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 208000005176 Hepatitis C Diseases 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001769 aryl amino group Chemical group 0.000 claims description 6
- 125000005110 aryl thio group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229960000329 ribavirin Drugs 0.000 claims description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 102100020870 La-related protein 6 Human genes 0.000 claims description 2
- 108050008265 La-related protein 6 Proteins 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 2
- 125000005248 alkyl aryloxy group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims description 2
- 125000005281 alkyl ureido group Chemical group 0.000 claims description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- 125000005421 aryl sulfonamido group Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- UTXKJLXAUOOWAC-UHFFFAOYSA-N azanylidyne-[[cyano(nitrosulfonyl)sulfinamoyl]-nitrosulfonylamino]methane Chemical compound [O-][N+](=O)S(=O)(=O)N(C#N)S(=O)N(C#N)S(=O)(=O)[N+]([O-])=O UTXKJLXAUOOWAC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 125000005518 carboxamido group Chemical group 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 2
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 125000005936 piperidyl group Chemical class 0.000 claims description 2
- 125000004076 pyridyl group Chemical class 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000001544 thienyl group Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 57
- 239000000126 substance Substances 0.000 claims 53
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 20
- 239000003443 antiviral agent Substances 0.000 claims 12
- 230000001747 exhibiting effect Effects 0.000 claims 11
- 230000002401 inhibitory effect Effects 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 11
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 6
- 238000007920 subcutaneous administration Methods 0.000 claims 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 229910052754 neon Inorganic materials 0.000 claims 3
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- GFZMFCVDDFHSJK-UHFFFAOYSA-N 2-(methylideneamino)acetonitrile Chemical compound C=NCC#N GFZMFCVDDFHSJK-UHFFFAOYSA-N 0.000 claims 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 101100439253 Arabidopsis thaliana CHI3 gene Proteins 0.000 claims 1
- 239000008000 CHES buffer Substances 0.000 claims 1
- 101001072091 Homo sapiens ProSAAS Proteins 0.000 claims 1
- 101100240462 Homo sapiens RASAL2 gene Proteins 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims 1
- 229910004734 Oy H Inorganic materials 0.000 claims 1
- 241001302890 Parachondrostoma toxostoma Species 0.000 claims 1
- 102100036366 ProSAAS Human genes 0.000 claims 1
- 102100035410 Ras GTPase-activating protein nGAP Human genes 0.000 claims 1
- 235000014548 Rubus moluccanus Nutrition 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- FESBVLZDDCQLFY-UHFFFAOYSA-N sete Chemical compound [Te]=[Se] FESBVLZDDCQLFY-UHFFFAOYSA-N 0.000 claims 1
- 125000006000 trichloroethyl group Chemical group 0.000 claims 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 claims 1
- OIWCYIUQAVBPGV-DAQGAKHBSA-N {1-O-hexadecanoyl-2-O-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}serine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC OIWCYIUQAVBPGV-DAQGAKHBSA-N 0.000 claims 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 10
- 108010022999 Serine Proteases Proteins 0.000 description 9
- 102000012479 Serine Proteases Human genes 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- WYVKPHCYMTWUCW-YUPRTTJUSA-N Cys-Thr Chemical group C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)N)O WYVKPHCYMTWUCW-YUPRTTJUSA-N 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101100129514 Mus musculus Mbip gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010049219 RNA-dependent ATPase Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
- 102000057815 human SPINK1 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000004797 ketoamides Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22010800P | 2000-07-21 | 2000-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200210312B true ZA200210312B (en) | 2004-03-29 |
Family
ID=22822095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200210312A ZA200210312B (en) | 2000-07-21 | 2002-12-19 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. |
Country Status (32)
Country | Link |
---|---|
US (4) | US7012066B2 (pl) |
EP (1) | EP1385870B1 (pl) |
JP (3) | JP4298289B2 (pl) |
KR (2) | KR100939155B1 (pl) |
CN (3) | CN102206247B (pl) |
AR (2) | AR033985A1 (pl) |
AT (1) | ATE461207T1 (pl) |
AU (2) | AU7698801A (pl) |
BR (1) | BR0112540A (pl) |
CA (1) | CA2410662C (pl) |
CY (2) | CY1112267T1 (pl) |
CZ (1) | CZ303213B6 (pl) |
DE (2) | DE60141608D1 (pl) |
DK (1) | DK1385870T3 (pl) |
EC (1) | ECSP034438A (pl) |
ES (1) | ES2341534T3 (pl) |
HK (1) | HK1058047A1 (pl) |
HU (1) | HU229997B1 (pl) |
IL (2) | IL153670A0 (pl) |
LU (1) | LU91910I2 (pl) |
MX (1) | MXPA03000627A (pl) |
MY (2) | MY143322A (pl) |
NO (2) | NO332329B1 (pl) |
NZ (1) | NZ523782A (pl) |
PL (1) | PL206255B1 (pl) |
PT (1) | PT1385870E (pl) |
RU (2) | RU2355700C9 (pl) |
SI (1) | SI1385870T1 (pl) |
SK (1) | SK288064B6 (pl) |
TW (1) | TWI324611B (pl) |
WO (1) | WO2002008244A2 (pl) |
ZA (1) | ZA200210312B (pl) |
Families Citing this family (262)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
ATE461207T1 (de) * | 2000-07-21 | 2010-04-15 | Schering Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
AU2001291013A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
GB2367816A (en) * | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
AU2002236591B2 (en) * | 2000-12-12 | 2005-07-14 | Schering Corporation | Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus |
EP1404704B9 (en) | 2001-07-11 | 2008-02-20 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
MXPA04003825A (es) * | 2001-10-24 | 2004-07-08 | Vertex Pharma | Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado. |
MXPA04007163A (es) | 2002-01-23 | 2004-10-29 | Schering Corp | Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c. |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CN100381440C (zh) * | 2002-04-11 | 2008-04-16 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂 |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
ES2381548T3 (es) * | 2003-04-11 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente de la proteasa VHC NS3-NS4A |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
UA83046C2 (ru) | 2003-05-21 | 2008-06-10 | Берингер Ингельхайм Интернациональ Гмбх | Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе |
CN101823965B (zh) * | 2003-06-17 | 2012-12-19 | 默沙东公司 | 制备(1r,2s,5s)-6,6-二甲基-3-氮杂双环[3,1,0]己烷-2-羧酸酯或其盐的方法和中间体 |
AR044694A1 (es) | 2003-06-17 | 2005-09-21 | Schering Corp | Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo |
US6992220B2 (en) | 2003-06-17 | 2006-01-31 | Schering Corporation | Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof |
CN102020700A (zh) | 2003-07-18 | 2011-04-20 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
MXPA06002250A (es) * | 2003-08-26 | 2006-05-17 | Schering Corp | Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c. |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
CA2538791A1 (en) * | 2003-09-18 | 2005-03-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
BRPI0414814A (pt) * | 2003-09-26 | 2006-11-14 | Schering Corp | inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c |
KR20120010278A (ko) | 2003-10-10 | 2012-02-02 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의 억제제 |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1944042A1 (en) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Combinations for HCV treatment |
US8187874B2 (en) | 2003-10-27 | 2012-05-29 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
AU2004285019B9 (en) | 2003-10-27 | 2011-11-24 | Vertex Pharmaceuticals Incorporated | HCV NS3-NS4A protease resistance mutants |
JP2007532479A (ja) | 2003-11-20 | 2007-11-15 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター |
AU2004298498B2 (en) * | 2003-12-11 | 2008-09-11 | Schering Corporation | Inhibitors of hepatitis C virus NS3/NS4a serine protease |
WO2005070955A1 (en) | 2004-01-21 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
ES2342944T3 (es) * | 2004-01-30 | 2010-07-19 | Medivir Ab | Inhibidores de ns-3 serina proteasa de vhc. |
CA2554999A1 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
JP4143669B2 (ja) | 2004-02-24 | 2008-09-03 | 日本たばこ産業株式会社 | 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
TW200529823A (en) * | 2004-02-27 | 2005-09-16 | Schering Corp | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
US8067379B2 (en) * | 2004-02-27 | 2011-11-29 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
CN1946692A (zh) * | 2004-02-27 | 2007-04-11 | 先灵公司 | 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的3,4-(环戊基)-稠合的脯氨酸化合物 |
US7816326B2 (en) | 2004-02-27 | 2010-10-19 | Schering Corporation | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
KR20070026394A (ko) | 2004-02-27 | 2007-03-08 | 쉐링 코포레이션 | C형 간염 바이러스의 ns3 세린 프로테아제 억제제로서사이클릭 p4's를 지닌 신규한 케토아미드 |
TW200602037A (en) * | 2004-02-27 | 2006-01-16 | Schering Corp | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease |
WO2005085197A1 (en) * | 2004-02-27 | 2005-09-15 | Schering Corporation | Cyclobutenedione groups-containing compounds as inhibitors of hepatitis c virus ns3 serine protease |
WO2005085275A1 (en) | 2004-02-27 | 2005-09-15 | Schering Corporation | Inhibitors of hepatitis c virus ns3 protease |
HUE024556T2 (hu) * | 2004-03-12 | 2016-02-29 | Vertex Pharma | Eljárások és intermedierek aszparagin acetál kapszáz inhibitorok elõállítására |
WO2005107745A1 (en) * | 2004-05-06 | 2005-11-17 | Schering Corporation | An inhibitor of hepatitis c |
DE602005015452D1 (de) * | 2004-05-20 | 2009-08-27 | Schering Corp | Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
MX2007002371A (es) | 2004-08-27 | 2007-04-23 | Schering Corp | Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
KR20070061570A (ko) | 2004-10-01 | 2007-06-13 | 버텍스 파마슈티칼스 인코포레이티드 | Hcv ns3-ns4a 프로테아제 저해 |
US7196161B2 (en) * | 2004-10-01 | 2007-03-27 | Scynexis Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection |
MX2007003538A (es) * | 2004-10-01 | 2008-01-16 | Scynexis Inc | Derivados de ciclosporina 3-eter y 3-tioeter sustituidos para el tratamiento y prevencion de infeccion de hepatitis c. |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
GB0426661D0 (en) * | 2004-12-06 | 2005-01-05 | Isis Innovation | Pyrrolidine compounds |
US20060275366A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
US20070021351A1 (en) * | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
AU2006252519B2 (en) | 2005-06-02 | 2012-08-30 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
WO2006130626A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period |
WO2006130554A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
WO2006130552A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
AU2006252553B2 (en) * | 2005-06-02 | 2012-03-29 | Merck Sharp & Dohme Corp. | Combination of HCV protease inhibitors with a surfactant |
NZ563369A (en) * | 2005-06-02 | 2011-03-31 | Schering Corp | Controlled-release formulation useful for treating disorders associated with hepatitus C virus |
US20060276405A1 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis C |
TWI449711B (zh) * | 2005-06-30 | 2014-08-21 | Virobay Inc | C型肝炎病毒(hcv)抑制劑 |
US7608592B2 (en) * | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
US20090148407A1 (en) | 2005-07-25 | 2009-06-11 | Intermune, Inc. | Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication |
JP5230416B2 (ja) | 2005-07-29 | 2013-07-10 | テイボテク・フアーマシユーチカルズ | C型肝炎ウイルスの大員環状阻害剤 |
ATE524475T1 (de) | 2005-07-29 | 2011-09-15 | Tibotec Pharm Ltd | Makrocyclische inhibitoren des hepatitis-c-virus |
AU2006275413B2 (en) * | 2005-08-02 | 2012-07-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
CN102382170A (zh) | 2005-08-19 | 2012-03-21 | 弗特克斯药品有限公司 | 用于制备蛋白酶抑制剂的方法和中间体 |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
WO2007041631A1 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION |
CA2623865A1 (en) * | 2005-09-30 | 2007-04-12 | Scynexis, Inc. | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection |
DK1999129T3 (da) * | 2005-10-11 | 2011-02-07 | Intermune Inc | Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus |
US7528142B2 (en) | 2005-11-03 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
CN101405295A (zh) | 2005-11-11 | 2009-04-08 | 沃泰克斯药物股份有限公司 | 丙型肝炎病毒变种 |
AR056805A1 (es) | 2005-11-14 | 2007-10-24 | Schering Corp | Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados |
MX2008008350A (es) * | 2005-12-22 | 2008-09-03 | Schering Corp | Procedimiento para la preparacion de compuestos 6,6-dimetil-3-azabiciclo-[3.1.0]-hexano y sales enantiomericas del mismo. |
EP2386539B1 (en) | 2005-12-23 | 2016-07-20 | Zealand Pharma A/S | 4-Aminoproline derivatives useful as lysine mimetics |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
AR059429A1 (es) * | 2006-02-09 | 2008-04-09 | Schering Corp | Combinaciones que involucran el (los) inhibidor(es) de la protesa hcv y metodos de tratamiento relacionados al (los) mismo (s) |
WO2007092645A2 (en) * | 2006-02-09 | 2007-08-16 | Schering Corporation | Novel hcv inhibitor combinations and methods |
WO2007098270A2 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same |
US20090220457A1 (en) * | 2006-03-03 | 2009-09-03 | Lahser Frederick C | Combinations comprising hcv protease inhibitor(s) and hcv ires inhibitor(s), and methods of treatment related thereto |
US20070207122A1 (en) * | 2006-03-06 | 2007-09-06 | Kempf Dale J | Compositons and methods of use of ritonavir for treating hcv |
BRPI0709567A2 (pt) | 2006-03-16 | 2011-07-12 | Vertex Pharma | inibidores deuterados de protease de hepatite c |
EP2007788A2 (en) * | 2006-04-11 | 2008-12-31 | Novartis AG | Hcv inhibitors |
US20080045530A1 (en) * | 2006-04-11 | 2008-02-21 | Trixi Brandl | Organic Compounds and Their Uses |
NZ571826A (en) * | 2006-04-11 | 2012-01-12 | Novartis Ag | HCV/HIV inhibitors and their uses |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
SG172690A1 (en) * | 2006-04-28 | 2011-07-28 | Schering Corp | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
US8420122B2 (en) * | 2006-04-28 | 2013-04-16 | Merck Sharp & Dohme Corp. | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
CN101495095B (zh) * | 2006-04-28 | 2013-05-29 | 默沙东公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
DK2023918T3 (da) | 2006-05-19 | 2011-04-26 | Scynexis Inc | Cyclosporiner til behandlingen og forebyggelse af okulære lidelser |
US7951823B2 (en) | 2006-05-23 | 2011-05-31 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
PL2019837T3 (pl) * | 2006-05-23 | 2011-09-30 | Irm Llc | Związki i kompozycje jako inhibitory proteazy aktywującej kanały |
CN101502196A (zh) * | 2006-06-02 | 2009-08-05 | 克洛德·安妮·佩里西恩 | 激活电子的管理 |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
CA2660555A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
WO2008024763A2 (en) * | 2006-08-25 | 2008-02-28 | Wyeth | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
CN101541826A (zh) * | 2006-09-13 | 2009-09-23 | 诺瓦提斯公司 | 大环hcv抑制剂及其用途 |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7576057B2 (en) | 2006-11-20 | 2009-08-18 | Scynexis, Inc. | Cyclic peptides |
EP2099778A2 (en) * | 2006-11-21 | 2009-09-16 | Smithkline Beecham Corporation | Amido anti-viral compounds |
JP2010510245A (ja) * | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス化合物 |
CA2673111A1 (en) * | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
MX2009006477A (es) * | 2006-12-15 | 2009-06-26 | Schering Corp | Purificacion de bisulfito de una alfa-ceto amida. |
CN101611000B (zh) * | 2006-12-20 | 2013-08-21 | 默沙东公司 | (1r,2s,5s)-n-[(1s)-3-氨基-1-(环丁基甲基)-2,3-二氧代丙基]-3-[(2s)-2-[[[(1,1-二甲基乙基)氨基]-羰基]氨基]-3,3-二甲基-1-氧代丁基]-6,6-二甲基-3-氮杂双环[3.1.0]己烷-2-碳酰胺的制备方法 |
WO2008079266A2 (en) | 2006-12-21 | 2008-07-03 | Wyeth | Synthesis of pyrrolidine compounds |
MX2009006880A (es) | 2006-12-22 | 2009-07-03 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas. |
WO2008136815A2 (en) | 2006-12-22 | 2008-11-13 | Schering Corporation | 5, 6-ring annulated indole derivatives and use thereof |
KR20090106539A (ko) * | 2006-12-22 | 2009-10-09 | 쉐링 코포레이션 | Hcv 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
US20080161254A1 (en) * | 2007-01-03 | 2008-07-03 | Virobay, Inc. | Hcv inhibitors |
EA016327B1 (ru) * | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
TW200846343A (en) | 2007-02-27 | 2008-12-01 | Vertex Pharma | Co-crystals and pharmaceutical compositions comprising the same |
CA2679426A1 (en) | 2007-02-27 | 2008-09-04 | Luc Farmer | Inhibitors of serine proteases |
MX2009010205A (es) * | 2007-03-23 | 2009-10-19 | Schering Corp | Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c. |
JP2010528987A (ja) * | 2007-05-03 | 2010-08-26 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
EP2494991A1 (en) | 2007-05-04 | 2012-09-05 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of HCV infection |
AR066528A1 (es) * | 2007-05-10 | 2009-08-26 | Array Biopharma Inc | Peptidos inhibidores de la replicacion del virus de la hepatitis c |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
KR20100067652A (ko) | 2007-08-29 | 2010-06-21 | 쉐링 코포레이션 | 치환된 인돌 유도체 및 이의 사용방법 |
JP5258889B2 (ja) | 2007-08-29 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | ウイルス感染症の治療のための2,3−置換アザインドール誘導体 |
TW200924751A (en) * | 2007-08-29 | 2009-06-16 | Schering Corp | 2,3-substituted indole derivatives and methods of use thereof |
CL2008002549A1 (es) | 2007-08-30 | 2010-09-03 | Vertex Pharma | Cocristal que comprende vx-950 y un formador de cocristal seleccionado de acido 3-metoxi-4hidroxibenzoico,acido 2,4-dihidroxibenzoico y acido 2,5-dihidroxibenzoico; metodo de preparacion; composicion farmaceutica que comprende el cocristal, util como agente antiviral en el tratamiento del hcv. |
EP2489369A1 (en) * | 2007-09-14 | 2012-08-22 | Merck Sharp & Dohme Corp. | A method of treating Hepatitis C patients |
CA2702132A1 (en) * | 2007-10-10 | 2009-04-16 | Novartis Ag | Spiropyrrolidines and their use against hcv and hiv infection |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
CA2705586A1 (en) * | 2007-11-16 | 2009-05-22 | Schering Corporation | 3-heterocyclic substituted indole derivatives and methods of use thereof |
CN102317285A (zh) * | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
JP2011504929A (ja) * | 2007-11-28 | 2011-02-17 | シェーリング コーポレイション | 6,6−ジメチル−3−アザビシクロ[3.1.0]ヘキサンを提供するのに有用な中間体調製のための脱塩化水素化プロセス |
NZ585370A (en) | 2007-12-19 | 2012-09-28 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
CN102089274B (zh) * | 2007-12-21 | 2014-09-10 | 默沙东公司 | 合成3-氨基-3-环丁基甲基-2-羟基丙酰胺或其盐的方法 |
MX2010008523A (es) * | 2008-02-04 | 2010-08-31 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa. |
US8048862B2 (en) * | 2008-04-15 | 2011-11-01 | Intermune, Inc. | Macrocyclic inhibitors of hepatitis C virus replication |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102046648A (zh) | 2008-05-29 | 2011-05-04 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
CA2724523A1 (en) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
WO2009148615A1 (en) * | 2008-06-06 | 2009-12-10 | Scynexis, Inc. | Cyclosporin analogs and their use in the treatment of hcv infections |
JP5580814B2 (ja) * | 2008-06-13 | 2014-08-27 | メルク・シャープ・アンド・ドーム・コーポレーション | 3環式インドール誘導体およびその使用方法 |
MX2010014500A (es) | 2008-06-24 | 2011-05-30 | Codexis Inc | Procedimientos biocataliticos para la preparacion de compuestos de prolina biciclica fusionada sustancialmente estereomericamente puros. |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
EP2326628A1 (en) | 2008-08-20 | 2011-06-01 | Schering Corporation | Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
TWI409265B (zh) | 2008-08-20 | 2013-09-21 | Merck Sharp & Dohme | 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途 |
AR072940A1 (es) | 2008-08-20 | 2010-09-29 | Schering Corp | Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales |
JP5619743B2 (ja) | 2008-08-20 | 2014-11-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用 |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AP2011005695A0 (en) * | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102307892A (zh) * | 2008-12-31 | 2012-01-04 | 西尼克斯公司 | 环孢菌素a的衍生物 |
JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体 |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
US8102720B2 (en) * | 2009-02-02 | 2012-01-24 | Qualcomm Incorporated | System and method of pulse generation |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
JP5690286B2 (ja) | 2009-03-04 | 2015-03-25 | イデニク プハルマセウティカルス,インコーポレイテッド | ホスホチオフェン及びホスホチアゾールhcvポリメラーゼ阻害剤 |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US8512690B2 (en) * | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) * | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US20120244122A1 (en) | 2009-05-28 | 2012-09-27 | Masse Craig E | Peptides for the Treatment of HCV Infections |
WO2010138791A1 (en) | 2009-05-29 | 2010-12-02 | Schering Corporation | Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c |
WO2010151488A1 (en) | 2009-06-23 | 2010-12-29 | Gilead Sciences, Inc. | Combination of boceprevir with 5- ( { 6- [2, 4- bis (trifluoromethyl) phenyl] pyridazin-3 -yl } methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c] pyridine for the treatment of hcv |
WO2011016576A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Alanine derivatives as inhibitors of apoptosis proteins |
CA2769652A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
WO2011031904A1 (en) | 2009-09-11 | 2011-03-17 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
AU2010298028A1 (en) * | 2009-09-28 | 2012-04-19 | Intermune, Inc. | Cyclic peptide inhibitors of hepatitis C virus replication |
TW201116540A (en) * | 2009-10-01 | 2011-05-16 | Intermune Inc | Therapeutic antiviral peptides |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
KR20120118008A (ko) | 2009-12-18 | 2012-10-25 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 c 바이러스 억제제 |
AU2010341537A1 (en) | 2009-12-22 | 2012-08-09 | Merck Sharp & Dohme Corp. | Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases |
WO2011103441A1 (en) | 2010-02-18 | 2011-08-25 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
MX2012009926A (es) * | 2010-02-25 | 2012-10-05 | Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg | Un proceso para la preparacion de peptidos prolil sustituidos y peptidomimeticos similares. |
SG183526A1 (en) | 2010-03-09 | 2012-09-27 | Merck Sharp & Dohme | Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases |
WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
WO2012050848A1 (en) | 2010-09-29 | 2012-04-19 | Schering Corporation | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
SG194485A1 (en) | 2011-04-13 | 2013-12-30 | Merck Sharp & Dohme | 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
EP2755981A4 (en) | 2011-09-14 | 2015-03-25 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
SE1450019A1 (sv) | 2011-10-21 | 2014-01-10 | Abbvie Inc | Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
MX2014004729A (es) | 2011-10-21 | 2014-07-28 | Abbvie Inc | Tratamiento en combinacion (por ejemplo, con abt-072 o abt-333) de agentes antivirales de accion directa para utilizarse en el tratamiento del virus de la hepatitis c. |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
WO2013072327A1 (en) | 2011-11-14 | 2013-05-23 | Sanofi | Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases |
AR091192A1 (es) * | 2012-05-30 | 2015-01-21 | Chemo Iberica Sa | Procedimiento multicomponente para la preparacion de compuestos biciclicos |
CN103508918B (zh) * | 2012-06-18 | 2015-09-09 | 上海医药工业研究院 | 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法 |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
WO2014061034A1 (en) * | 2012-10-18 | 2014-04-24 | Msn Laboratories Limited | Process for preparation of boceprevir and intermediates thereof |
BR112015007879A2 (pt) | 2012-10-19 | 2017-07-04 | Bristol Myers Squibb Co | inibidores do vírus da hepatite c |
AU2013340559B2 (en) | 2012-10-29 | 2018-03-15 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014083575A2 (en) | 2012-11-29 | 2014-06-05 | Mylan Laboratories Ltd | Improved process for the preparation of boceprevir intermediate |
CN103936652B (zh) * | 2013-01-18 | 2016-07-06 | 上海医药工业研究院 | 抗丙肝药物Boceprevir的中间体IV及其制备方法和应用 |
CN103936818B (zh) * | 2013-01-18 | 2017-09-29 | 上海医药工业研究院 | 抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用 |
CN103936627B (zh) * | 2013-01-18 | 2016-08-31 | 上海医药工业研究院 | 抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用 |
EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
UY35455A (es) | 2013-03-14 | 2014-09-30 | Onyx Therapeutics Inc | Inhibidores tripeptidicos de la epoxicetona proteasa |
AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
CN103387510B (zh) * | 2013-08-08 | 2015-09-09 | 苏州永健生物医药有限公司 | 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法 |
WO2015042375A1 (en) | 2013-09-20 | 2015-03-26 | Idenix Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
EP3060554A1 (en) * | 2013-10-24 | 2016-08-31 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US10167298B2 (en) | 2013-10-30 | 2019-01-01 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof |
EP2899207A1 (en) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | New method for testing HCV protease inhibition |
US20170135990A1 (en) | 2014-03-05 | 2017-05-18 | Idenix Pharmaceuticals Llc | Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection |
WO2015134560A1 (en) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Solid forms of a flaviviridae virus inhibitor compound and salts thereof |
CN106810485A (zh) * | 2015-11-27 | 2017-06-09 | 上海现代制药股份有限公司 | 一种手性联苯吡咯烷酮的制备方法及其中间体 |
CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
EP4257191A3 (en) * | 2016-06-21 | 2023-11-22 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
WO2017222917A1 (en) * | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Aliphatic prolinamide derivatives |
US10526315B2 (en) | 2016-06-21 | 2020-01-07 | Orion Ophthalmology LLC | Carbocyclic prolinamide derivatives |
WO2018073110A1 (en) | 2016-10-20 | 2018-04-26 | Basf Se | Quinoline compounds as fungicides |
CN110191881A (zh) | 2017-01-23 | 2019-08-30 | 巴斯夫欧洲公司 | 杀真菌的吡啶化合物 |
WO2018184882A1 (en) | 2017-04-06 | 2018-10-11 | Basf Se | Pyridine compounds |
ES2870106T3 (es) | 2017-05-05 | 2021-10-26 | Zealand Pharma As | Moduladores de la comunicación intercelular de uniones comunicantes y su uso para el tratamiento de la enfermedad del ojo diabético |
EP3927703B1 (en) | 2019-02-19 | 2023-04-05 | Univerza V Ljubljani | Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold |
US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
WO2022109360A1 (en) | 2020-11-23 | 2022-05-27 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
IL307443A (en) * | 2021-04-16 | 2023-12-01 | Fujian Akeylink Biotechnology Co Ltd | A short ring-modified peptide compound of proline and its use |
US11970502B2 (en) | 2021-05-04 | 2024-04-30 | Enanta Pharmaceuticals, Inc. | Macrocyclic antiviral agents |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
CN114133350B (zh) * | 2021-12-16 | 2023-05-23 | 浙江乐普药业股份有限公司 | 一种抗新冠药物Paxlovid中间体的制备方法 |
WO2023149981A1 (en) * | 2022-02-07 | 2023-08-10 | Purdue Research Foundation | Compounds for the treatment of sars |
CN114736151B (zh) * | 2022-04-13 | 2023-04-21 | 湖南复瑞生物医药技术有限责任公司 | 一种帕罗韦德关键中间体制备方法及化合物的结构式 |
CN115160205B (zh) * | 2022-07-08 | 2024-06-07 | 上海皓鸿生物医药科技有限公司 | 一种制备(s)-1-(叔丁氧羰基)-2,5-二氢-1h-吡咯-2-羧酸及盐的方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU177134B (en) * | 1977-07-18 | 1981-07-28 | Richter Gedeon Vegyeszet | Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity |
DE2936099A1 (de) * | 1979-09-06 | 1981-04-02 | Victor Dipl.- Chem. 8000 München Brantl | Pharmakologisch aktive peptide |
JPS5781447A (en) * | 1980-11-11 | 1982-05-21 | Toyo Jozo Co Ltd | Human chorionic gonadotropic hormone c-terminal fragment |
DE3481913D1 (de) * | 1983-04-27 | 1990-05-17 | Ici America Inc | Prolin-derivate. |
AU600226B2 (en) | 1985-02-04 | 1990-08-09 | Merrell Pharmaceuticals Inc. | Novel peptidase inhibitors |
US5496927A (en) * | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
NZ227011A (en) | 1987-11-18 | 1992-03-26 | Chiron Corp | Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits |
ZA897514B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
EP0381216B1 (en) | 1989-02-01 | 1995-12-27 | Asahi Glass Company Ltd. | Hydrochlorofluorocarbon azeotropic or azeotropic-like mixture |
EP0672648B1 (en) | 1989-04-15 | 1998-09-23 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Threo (2R,3S)-3-amino-2-hydroxypentanoic acid and threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentanoic acid |
US5359138A (en) * | 1989-04-15 | 1994-10-25 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Poststatin and related compounds or salts thereof |
EP1304335B1 (en) | 1990-04-04 | 2009-06-10 | Novartis Vaccines and Diagnostics, Inc. | Hepatitis C virus protease |
JP2804817B2 (ja) | 1990-04-13 | 1998-09-30 | 財団法人微生物化学研究会 | 3―アミノ―2―オキソ脂肪酸誘導体の製造法 |
JPH04149166A (ja) | 1990-10-12 | 1992-05-22 | Nippon Kayaku Co Ltd | 新規ケト酸アミド誘導体 |
AU667463B2 (en) | 1990-12-28 | 1996-03-28 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of neurodegeneration |
FR2686086A1 (fr) * | 1992-01-15 | 1993-07-16 | Adir | Nouveaux derives de peptides et de pseudopeptides therapeutiquement actifs dans la cascade de coagulation sanguine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
DE69333269T2 (de) * | 1992-01-31 | 2004-07-29 | Abbott Laboratories, Abbott Park | Expressionssystem in säugetieren für hcv-proteine |
WO1994000095A2 (en) | 1992-06-24 | 1994-01-06 | Cortex Pharmaceuticals, Inc. | Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity |
US5514694A (en) * | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
US5414018A (en) * | 1993-09-24 | 1995-05-09 | G. D. Searle & Co. | Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension |
US5843450A (en) * | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
IT1272179B (it) * | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
US5500208A (en) | 1994-06-07 | 1996-03-19 | The Procter & Gamble Company | Oral compositions comprising a novel tripeptide |
US6285380B1 (en) * | 1994-08-02 | 2001-09-04 | New York University | Method and system for scripting interactive animated actors |
US5843752A (en) * | 1995-05-12 | 1998-12-01 | Schering Corporation | Soluble active hepatitis C virus protease |
US5919765A (en) | 1995-06-07 | 1999-07-06 | Cor Therapeutics, Inc. | Inhibitors of factor XA |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5763576A (en) * | 1995-10-06 | 1998-06-09 | Georgia Tech Research Corp. | Tetrapeptide α-ketoamides |
TW442452B (en) | 1996-03-01 | 2001-06-23 | Akzo Nobel Nv | Serine protease inhibitors having an alkynylamino side chain |
US5633388A (en) * | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5736576A (en) * | 1996-06-04 | 1998-04-07 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
AU4156197A (en) | 1996-08-21 | 1998-03-06 | Hybridon, Inc. | Oligonucleotide prodrugs |
IT1285158B1 (it) | 1996-09-17 | 1998-06-03 | Angeletti P Ist Richerche Bio | Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il |
DE69717652T2 (de) | 1996-09-24 | 2003-09-18 | Procter & Gamble | Flüssige reinigungsmittel, die proteolytisches enzym, peptidaldehyd und eine borsäurequelle enthalten |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
UA79749C2 (en) * | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6291640B1 (en) | 1996-12-27 | 2001-09-18 | Boehringer Ingelheim Ltd. | Peptidomimetic inhibitors of the human cytomegalovirus protease |
WO1998037180A2 (en) | 1997-02-22 | 1998-08-27 | Abbott Laboratories | Hcv fusion protease and polynucleotide encoding same |
IL134232A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides |
ATE283865T1 (de) * | 1997-08-11 | 2004-12-15 | Boehringer Ingelheim Ca Ltd | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6576613B1 (en) * | 1998-07-24 | 2003-06-10 | Corvas International, Inc. | Title inhibitors of urokinase |
AR022061A1 (es) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
JP2000256396A (ja) | 1999-03-03 | 2000-09-19 | Dainippon Pharmaceut Co Ltd | 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤 |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
JP2003526634A (ja) | 1999-12-03 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤 |
AU2001251165A1 (en) * | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
ATE461207T1 (de) * | 2000-07-21 | 2010-04-15 | Schering Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
AR029851A1 (es) * | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
-
2001
- 2001-07-19 AT AT01954764T patent/ATE461207T1/de active
- 2001-07-19 KR KR1020097002011A patent/KR100939155B1/ko not_active IP Right Cessation
- 2001-07-19 KR KR1020037000784A patent/KR100904788B1/ko not_active IP Right Cessation
- 2001-07-19 CZ CZ20030151A patent/CZ303213B6/cs not_active IP Right Cessation
- 2001-07-19 NZ NZ523782A patent/NZ523782A/en not_active IP Right Cessation
- 2001-07-19 AU AU7698801A patent/AU7698801A/xx active Pending
- 2001-07-19 BR BR0112540-0A patent/BR0112540A/pt not_active IP Right Cessation
- 2001-07-19 DE DE60141608T patent/DE60141608D1/de not_active Expired - Lifetime
- 2001-07-19 PL PL366063A patent/PL206255B1/pl unknown
- 2001-07-19 CN CN2011100651916A patent/CN102206247B/zh not_active Expired - Fee Related
- 2001-07-19 SI SI200130967T patent/SI1385870T1/sl unknown
- 2001-07-19 SK SK75-2003A patent/SK288064B6/sk not_active IP Right Cessation
- 2001-07-19 IL IL15367001A patent/IL153670A0/xx unknown
- 2001-07-19 RU RU2003105217/04A patent/RU2355700C9/ru not_active IP Right Cessation
- 2001-07-19 HU HU0401730A patent/HU229997B1/hu not_active IP Right Cessation
- 2001-07-19 JP JP2002514149A patent/JP4298289B2/ja not_active Expired - Fee Related
- 2001-07-19 US US09/908,955 patent/US7012066B2/en not_active Ceased
- 2001-07-19 WO PCT/US2001/022678 patent/WO2002008244A2/en active IP Right Grant
- 2001-07-19 PT PT01954764T patent/PT1385870E/pt unknown
- 2001-07-19 AU AU2001276988A patent/AU2001276988B2/en not_active Ceased
- 2001-07-19 CN CNA018131115A patent/CN1498224A/zh active Pending
- 2001-07-19 EP EP01954764A patent/EP1385870B1/en not_active Expired - Lifetime
- 2001-07-19 CN CN2011102287110A patent/CN102372764A/zh active Pending
- 2001-07-19 MX MXPA03000627A patent/MXPA03000627A/es active IP Right Grant
- 2001-07-19 ES ES01954764T patent/ES2341534T3/es not_active Expired - Lifetime
- 2001-07-19 DK DK01954764.5T patent/DK1385870T3/da active
- 2001-07-19 CA CA2410662A patent/CA2410662C/en not_active Expired - Fee Related
- 2001-07-19 MY MYPI20064737A patent/MY143322A/en unknown
- 2001-07-19 MY MYPI20013436A patent/MY139078A/en unknown
- 2001-07-20 TW TW090117804A patent/TWI324611B/zh not_active IP Right Cessation
- 2001-07-20 AR ARP010103450A patent/AR033985A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 ZA ZA200210312A patent/ZA200210312B/en unknown
- 2002-12-25 IL IL153670A patent/IL153670A/en active Protection Beyond IP Right Term
-
2003
- 2003-01-20 NO NO20030272A patent/NO332329B1/no not_active IP Right Cessation
- 2003-01-20 EC EC2003004438A patent/ECSP034438A/es unknown
-
2004
- 2004-02-06 HK HK04100762.2A patent/HK1058047A1/xx not_active IP Right Cessation
-
2005
- 2005-09-30 US US11/241,656 patent/US20060205672A1/en not_active Abandoned
-
2008
- 2008-06-30 RU RU2008126266/04A patent/RU2008126266A/ru not_active Application Discontinuation
- 2008-10-27 JP JP2008275159A patent/JP2009051860A/ja active Pending
- 2008-11-19 AR ARP080105033A patent/AR069373A2/es unknown
-
2010
- 2010-06-16 CY CY20101100554T patent/CY1112267T1/el unknown
- 2010-12-20 US US12/973,020 patent/US20110117057A1/en not_active Abandoned
-
2011
- 2011-04-22 US US13/068,159 patent/USRE43298E1/en active Active
- 2011-12-02 LU LU91910C patent/LU91910I2/fr unknown
- 2011-12-16 CY CY2011020C patent/CY2011020I1/el unknown
-
2012
- 2012-01-13 DE DE201212000004 patent/DE122012000004I1/de active Pending
- 2012-11-05 JP JP2012243691A patent/JP5775505B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-12 NO NO2013003C patent/NO2013003I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200210312B (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. | |
ZA200405304B (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | |
ZA200210311B (en) | Novel petides as NS3-serine protease inhibitors of hepatitis C virus. | |
ZA200405341B (en) | Proline compounds a NS3-serine protease inhibitors. | |
ZA200304382B (en) | Diaryl peptides as NS3-Serine protease inhibitors of hepatitis C virus. | |
CN1938332B (zh) | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 | |
ZA200602447B (en) | Macrocyclic inhibitors of HCV NS3 serine protease | |
CN1845920B (zh) | 作为丝氨酸蛋白酶、特别是hcvns3-ns4a蛋白酶的抑制剂的2-氨基-4-芳氧基-1-羰基吡咯烷衍生物 | |
KR101755058B1 (ko) | 특정 hcv ns5a 억제제 및 hcv ns3 프로테아제 억제제의 조합물 | |
CN102245599B (zh) | 作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽 | |
US8178531B2 (en) | Antiviral agents | |
US9060971B2 (en) | Combination pharmaceutical agents as inhibitors of HCV replication | |
US8822700B2 (en) | Hepatitis C virus inhibitors | |
US9156818B2 (en) | Hepatitis C virus inhibitors | |
ES2401661T3 (es) | Inhibidores de serina proteasas | |
ZA200207845B (en) | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties. | |
US20020068702A1 (en) | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | |
US20100221214A1 (en) | Linked dibenzimidazole derivatives | |
CA2683639A1 (en) | Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease | |
CN101857631A (zh) | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 | |
US20090060874A1 (en) | Bicyclic pyrrolidine derivatives | |
CN101679483A (zh) | 作为hcv ns3-蛋白酶抑制剂的酰肼-肽 | |
ZA200208014B (en) | Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties. | |
ZA200409162B (en) | Hepatitis C virus inhibitors. | |
MX2008011354A (es) | Combinaciones farmaceuticas de inhibidores de proteasa del virus de hepatitis c y del sitio interno de entrada ribosomal del virus de hepatitis c. |